BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Cipla Teams with Eli Lilly to Market Tirzepatide Under Yurpeak in India

Synopsis:


As quoted in the press release from Cipla and Eli Lilly, the companies will launch tirzepatide under the brand “Yurpeak” in India with six dosage strengths (2.5–15 mg) and pricing aligned with Mounjaro. The deal places Cipla in a marketing role while Lilly manufactures.


Source:
Cipla Limited Press Release (NSE Exchange Filings) | Published on Oct 23, 2025

Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.

Cipla Ltd. News Today

As quoted in the press release from Cipla and Eli Lilly (NSE Exchange Filings), the companies have entered into an agreement to market the drug tirzepatide in India under the brand name “Yurpeak”. This deal involves Cipla taking up the marketing rights while Eli Lilly continues manufacturing. The partnership covers six dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg) and pricing is set at the same level as the current brand in India.

Strategic Partnership Details

Cipla and Eli Lilly said on 23 October 2025 that Eli Lilly will manufacture tirzepatide, and Cipla will market and distribute the drug in India under the new brand name Yurpeak.

The drug is indicated for diabetes and obesity management and forms part of the class of therapies known as GIP/GLP-1 dual receptor agonists.

Also read: Hero MotoCorp Enters UK Market With MotoGB Tie-Up

CIPLA LTD

Trade

1590.8-54.29 (-3.30 %)

Updated - 24 October 2025
1625.10day high
DAY HIGH
1590.00day low
DAY LOW
1678095
VOLUME (BSE)

Product Specifications Table

Feature

Detail

Active Ingredient

Tirzepatide

Brand Name in India

Yurpeak

Marketing Partner

Cipla

Manufacturing Partner

Eli Lilly

Dose Strengths

2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg

Pricing

Set equal to Mounjaro in India

Market Implications For Cipla Ltd.’s Share Price

As of 23 October 2025, 15:30 IST, Cipla Ltd’s share price on the NSE stood at ₹1,645.00, marking a decline of ₹ 18.60 (1.12%) from the previous close of ₹ 1,663.60.

Regulatory And Supply Considerations

Tirzepatide, a GIP/GLP-1 dual receptor agonist, has been studied and demonstrated cardiovascular and metabolic benefits in international trials.

The partners have indicated that the product will launch under Yurpeak once local regulatory approvals are in place. Eli Lilly had earlier signalled its intent to launch its Mounjaro version in India by 2025. Supply will remain with Eli Lilly’s manufacturing infrastructure, while Cipla will manage distribution and promotion.

Also read: BLS International Secures Visa Service Contracts in Kazakhstan & China

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.6 App Rating

icon-with-text

4 Languages

icon-with-text

₹6,800+ Cr MTF Book

icon-with-text